Description
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company was founded in 2007 and is headquartered in Bundoora, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.06
Trade Value (12mth)
AU$1,984.00
1 week
14.29%
1 month
4.35%
YTD
-45.45%
1 year
-46.67%
All time high
0.375106
EPS 3 yr Growth
-57.300%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-115.30%
ROIC
-109.00%
Interest Coverage
-67.20
Quick Ratio
1.30
Shares on Issue (Fully Dilluted)
324m
HALO Sector
Healthcare
Next Company Report Date
23-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 17 |
Conference Presentation
×
Conference Presentation |
31 May 23 |
Change of Director's Interest Notice x 2 (TO & DF)
×
Change of Director's Interest Notice x 2 (TO & DF) |
31 May 23 |
Change in substantial holding
×
Change in substantial holding |
31 May 23 |
Change in substantial holding
×
Change in substantial holding |
31 January 19 |
Investor and analyst briefing presentation
×
Investor and analyst briefing presentation |
30 October 19 |
AusBiotech Conference Presentation
×
AusBiotech Conference Presentation |
30 July 20 |
Investor presentation including future milestones
×
Investor presentation including future milestones |
30 January 23 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
30 April 20 |
Investor Presentation
×
Investor Presentation |
29 October 21 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 November 21 |
AGM presentations & first iCAR-T data
×
AGM presentations & first iCAR-T data |
29 November 21 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 May 23 |
Investor Summit live and recorded presentation
×
Investor Summit live and recorded presentation |
29 May 23 |
Application for quotation of securities - 1AD
×
Application for quotation of securities - 1AD |
29 May 23 |
Top 20 Option Holders & Distribution Schedule
×
Top 20 Option Holders & Distribution Schedule |
29 June 23 |
AD-214 clinical trial approval
×
AD-214 clinical trial approval |
29 August 22 |
Preliminary Final Report
×
Preliminary Final Report |
29 August 22 |
Annual Report to shareholders
×
Annual Report to shareholders |
29 August 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 August 19 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 November 18 |
AGM Presentation
×
AGM Presentation |
28 November 18 |
Results of Annual General Meeting 28 November 2018
×
Results of Annual General Meeting 28 November 2018 |
28 April 23 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
28 April 23 |
Rights Offer to fund early return to clinic and growth
×
Rights Offer to fund early return to clinic and growth |
28 April 23 |
Proposed issue of securities - 1AD
×
Proposed issue of securities - 1AD |
28 April 23 |
Prospectus
×
Prospectus |
28 April 23 |
Target Market Determination
×
Target Market Determination |
28 April 23 |
Letter to Optionholders
×
Letter to Optionholders |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.